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There is emerging evidence of high mortality rates after
the first diagnosis of psychotic disorder. The objective of
this study was to estimate the standardized mortality ratio
(SMR) in a population-based cohort of individuals with a
first diagnosis of schizophrenia-spectrum psychotic disorder
(SSD). The cohort included a population-based sample of
individuals with a first diagnosis of SSD based on the first diagnosis occurring during hospitalization or in an outpatient
setting between 2007 and 2010 in Ontario, Canada. All patients were followed for 5 years after the first diagnosis. The
primary outcome was SMR, including all-cause, suiciderelated, accidental, and other causes. Between 2007 and
2010, there were 2382 patients in the hospitalization cohort
and 11 003 patients in the outpatient cohort. Over the 5-year
observation period, 97 (4.1%) of the hospitalization cohort
and 292 (2.7%) of the outpatient cohort died, resulting in an
SMR of 13.6 and 9.1, respectively. In both cohorts, suicide
was the most common cause of death. Approximately 1 in
25 patients with a first diagnosis of SSD during hospitalization, and 1 in 40 patients with a first diagnosis of SSD in
an outpatient setting, died within 5 years of first diagnosis
in Ontario, Canada. This mortality rate is between 9 and
13 times higher than would be expected in the age-matched
general population. Based on these data, timely access to
services should be a public health priority to reduce mortality following a first diagnosis of an SSD.

spectrum psychotic disorder [SSD]), have excess mortality reducing their lifespan by up to 15 years.1,2 The
main causes of this excess mortality are cardiovascular
disease and suicide.1,2 However, the causes and risk of
mortality are not equally distributed throughout the
life span of an individual with SSD. In younger people,
after a first diagnosis, the main causes of the elevated
risk of mortality appears to be suicide and suiciderelated injury,3 not cardiovascular disease. These findings are corroborated by a recent study suggesting that
individuals with schizophrenia are more likely to die by
suicide at a younger age than individuals who have died
by suicide without a diagnosis of schizophrenia.4 The
early mortality observed in individuals following a first
diagnosis of SSD is striking for two reasons. First, the
causes of death in this period appear to be related more
to suicide than early manifestations of chronic diseases,
such as cardiovascular disease, which are more likely to
appear later in the lifespan.5 Second, there is evidence
that early mortality may be preventable with access to
adequate resources.6 Thus, there is early evidence that
suggests that mortality early after the onset of schizophrenia is both more common than once thought
and potentially preventable if individuals have access to
high-quality care.
The objective of the present study was to estimate
the risk of mortality among a population-based cohort
of individuals with a first diagnosis of SSD and to estimate standardized mortality rates by comparing to mortality rates, including cause-specific mortality rates, in
an age-matched general population comparison group.
Secondary objectives included determining access to
health services 30 days and 1 year following the first SSD

Key words: schizophrenia/first episode/mortality
Introduction
Individuals with psychotic disorders, such as schizophrenia and schizoaffective disorders (ie, a schizophrenia-
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diagnosis and, among those who died, 30 days and 1 year
preceding their death.
Methods
Study Design and Data Sources

Participants
Individuals were assigned to two separate cohorts
depending on the site of first diagnosis. The validated diagnostic algorithm to detect individuals with a psychotic
disorder requires either one SSD diagnosis (DSM-IV
codes 295.x; ICD9 code 295) from a hospitalization or
three physician-based diagnoses of SSD over a period
of 36 months.8 We created two separate cohorts, one in
which individuals were enrolled based on the SSD diagnosis during hospitalizations and one in which individuals were enrolled based on the three outpatient
diagnoses over 36 months. We need to create two cohorts
because calculating survival time between the two cohorts
was different. The outpatient cohort has a survival bias
based on the requirement of three diagnoses (eg, up to an
extra 36 months of survival required to enter the cohort),
whereas hospitalized cohort patients enter the cohort immediately, making the survival time estimates between
the two cohorts noncomparable. There is also some diagnostic uncertainty at the time of first diagnosis of

Outcomes
The primary outcome was all-cause mortality within
5 years of incident diagnosis. We also described the
number of different causes of death; due to the relatively
small number of deaths, we were only able to report on
three categories of mortality: accidental, suicide-related,
and “other” causes of death. The “other” category included all causes of mortality that were not accidental or
suicide-related causes, the most common of which were
related to cardiovascular disease.
We measured health service utilization 30 days and
1 year following incident diagnosis. We measured physician visits, including psychiatrist, primary care, and other
physician visits. We measured ED visits, categorized as
mental health-related and nonmental health-related. We
also measured ED visits related to suicide attempts, using
a validated diagnostic algorithm.11 We further measured hospitalizations, categorized as mental health- and
nonmental health-related. Among the patients who died
within 5 years of their incident schizophrenia diagnosis,
we measured the above health service utilization outcomes 30 days and 1 year prior to death date.
Data Analysis
We calculated standardized mortality ratios (SMRs),
which is the ratio between the observed number of deaths
in the SSD population compared with the expected
number of deaths based on the age- and sex-standardized
Ontario population, indirectly standardizing for both
age and sex.12 We also calculated SMRs stratified by sex,
by age category, and by cause of death. For all SMR
865
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We used a retrospective cohort design to identify all residents in Ontario, Canada with a first diagnosis of SSD
between January 1, 2007, and December 31, 2010, between 16 and 45 years of age. In Ontario, health care is
publicly funded,7 and the province’s population is nearly
15 million people. Individuals were followed for 5 years
following their cohort enrollment index date. The following datasets were used: the Ontario Health Insurance
Program (OHIP) database for information related to
physician visits, including diagnoses; the Ontario Mental
Health Reporting System (OMHRS) for information
about hospitalizations occurring in designated psychiatric beds; the Canadian Institute for Health Information
Discharge Abstract Database (CIHI-DAD) for information about hospitalizations occurring in nonpsychiatric
beds; the National Ambulatory Care Reporting System
(NACRS) for information related to Emergency
Department (ED) visits; the Registered Persons Database
(RPDB) for information related to patient demographics;
and the Ontario Registrar General Vital Statistics–Death
(ORGD) database for information on deaths, including
the cause of death. We also used Census data for information on neighborhood-level income. These datasets were
linked using unique encoded identifiers and analyzed
at ICES. The use of data in this project using anonymized data was authorized under section 45 of Ontario’s
Personal Health Information Protection Act, which does
not require review by a Research Ethics Board.

schizophrenia.9,10 Accordingly, we conducted a sensitivity
analysis using a separate cohort that included individuals with a diagnosis of psychotic disorder not otherwise
specified (DSM-IV and ICD9 code 298), in addition to
the individuals with schizophrenia and schizoaffective
disorder.
Individuals were excluded if they were younger than 16
or older than 45 years of age to capture individuals with
a first diagnosis of an SSD. They were also excluded if
they had a diagnosis of schizophrenia in the 12 months
prior to cohort enrollment to ensure we were enrolling
first episode (incident) cases of SSD. Patients were also
excluded if they were non-Ontario residents at the time
of diagnosis, or ineligible for OHIP in the year prior to
diagnosis. These individuals were excluded because we
would not know whether the diagnosis was a “first diagnosis”; it is possible that these individuals could have had
a prior diagnosis in another province, for example. For
the cohort that was enrolled via diagnosis during hospitalization, patients were excluded if their hospitalization
length of stay was less than 72 h (these “short stay” hospitalizations may not have accurate diagnoses).

P. Kurdyak et al

All analyses were completed using SAS Enterprise
Guide v9.4, with an ICES-created macro used for SMR
calculations.
Results
Between January 1, 2007, and December 31, 2010, 12
789 patients between the ages of 16 and 45 were enrolled in the cohort via outpatient encounters (Appendix
figure 1). After exclusions due to ineligibility of health
care coverage (N = 827) and those with a diagnosis of
a psychotic disorder 12 months prior to cohort entry
(N = 665), there were 11 297 outpatients with a diagnosis
of an SSD disorder. For the cohort with patients enrolled
via hospitalization, there were 6747 with a diagnosis of
SSD between the ages of 16 and 45 years. A total of 314
patients were excluded due to health care coverage ineligibility, and 392 patients were excluded who had a short

Table 1. Baseline demographic characteristics and health care utilization 1 y prior to cohort entry

Total
Demographic characteristics
Sex
Male
Female
Age (numeric, y)
Mean (SD)
Median (IQR)
Age categories (y)
16–20
21–25
26–30
31–35
36–40
41–45
Neighborhood income quintile
1 (low)
2 (medium–low)
3 (medium)
4 (medium–high)
5 (high)
Rural residence
No
Prior healthcare utilization*
Physician visits
No visits
PCP visit(s)
Psychiatrist visit(s)
PCP and psychiatrist visit(s)
ED visit
Mental health-related
Self-harm
Nonmental health-related
Hospitalization
Mental health-related
Nonmental health-related

Hospital cohort N (%)

Outpatient cohort N (%)

2382

11 003

Standardized difference

1547 (64.9%)
835 (35.1%)

6785 (61.7%)
4218 (38.3%)

0.07
0.07

30.15 ± 8.61
29 (22–38)

29.46 ± 8.61
28 (22–37)

0.08
0.08

379 (15.9%)
497 (20.9%)
398 (16.7%)
358 (15.0%)
355 (14.9%)
395 (16.6%)

2054 (18.7%)
2409 (21.9%)
1753 (15.9%)
1584 (14.4%)
1564 (14.2%)
1639 (14.9%)

0.07
0.03
0.02
0.02
0.02
0.05

763 (32.0%)
492 (20.7%)
423 (17.8%)
373 (15.7%)
297 (12.5%)

3381 (30.7%)
2323 (21.1%)
1906 (17.3%)
1803 (16.4%)
1512 (13.7%)

0.03
0.01
0.01
0.02
0.04

2148 (90.2%)

10 108 (91.9%)

0.06

384 (16.1%)
1758 (73.8%)
1049 (44.0%)
856 (35.9%)

1083 (9.8%)
9205 (83.7%)
4866 (44.2%)
4282 (38.9%)

0.19
0.24
0.00
0.06

585 (24.6%)
48 (2.0%)
982 (41.2%)

2428 (22.1%)
206 (1.9%)
4068 (37.0%)

0.06
0.01
0.09

500 (21.0%)
137 (5.8%)

1822 (16.6%)
508 (4.6%)

0.11
0.05

*Health care utilization was measured 1 y prior to the hospitalization date for patients in the hospitalization cohort or 1 y prior to the
first outpatient diagnosis for the outpatient cohort.
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calculations, we used Ontario’s population as of 2011
as the standard population (per Canadian Institute for
Health Information [CIHI] data and guidelines) to generate the expected number of deaths and SMRs.13 SMR
calculations were performed separately for each cohort
entry modality (hospital or outpatient setting).
We also conducted three sensitivity analyses producing mortality and standardized mortality rates in three
different cohorts. The first sensitivity analysis not only
included a cohort similar to the primary study cohort
but also included psychotic disorder not otherwise specified, a less specific diagnosis than schizophrenia or
schizoaffective disorder. In the second and third sensitivity analysis, we recreated our study cohort by revising
the algorithm for outpatient diagnoses to be less stringent. We created two separate cohorts by changing the
entry criteria to require only two diagnoses of SSD within
24 months and one diagnosis of SSD within 24 months.

Mortality After the First Diagnosis of Schizophrenia

Table 2. Characteristics of patients who died within the hospitaldiagnosed and outpatient-diagnosed cohorts
Hospital
cohort N (%)

Standardized
difference

97

292

0.08

65 (67.0%)
32 (33.0%)

211 (72.3%)
81 (27.7%)

0.11
0.11

34.13 (8.46)
34 (28–42)

32.25 (8.81)
33 (25–41)

0.22
0.21

8 (8.2%)
10 (10.3%)
14 (14.4%)
19 (19.6%)
18 (18.6%)
28 (28.9%)

33 (11.3%)
51 (17.5%)
43 (14.7%)
51 (17.5%)
37 (12.7%)
77 (26.4%)

0.10
0.21
0.01
0.05
0.16
0.06

18 (18.6%)
27 (27.8%)
52 (53.6%)

84 (28.8%)
88 (30.1%)
120 (41.1%)

0.24
0.05
0.21

Table 3. Mortality and SMRs
Hospital-diagnosed
cohort (N = 2382)

Total person-time
of follow-up (y)

All-cause mortality
11 613
Sex
Male
7543
Female
4070
Age category at cohort entry (y)
16–24
3895
25–29
2046
30–34
1770
35–39
1691
40–45
2211
Cause of death
Accidental
11 613
Suicide
11 613
Other*
11 613
Outpatient-diagnosed cohort N = 11 003
All-cause mortality
54 223
Sex
Male
33 360
Female
20 863
Age category at cohort entry (y)
16–24
20 044
25–29
9074
30–34
7829
35–39
7696
40–45
9580
Cause of death
Accidental
54 223
Suicide
54 223
Other*
54 223

Observed
deaths

Crude mortality
rate/1000 persons/y
(95% CI)

Expected
death count

SMR (95% CI)

SMR

97

8.35 (6.77–10.19)

7.12

13.62 (11.05–16.47)

13.62

65
32

8.62 (6.65–10.98)
7.86 (5.38–11.10)

4.37
2.76

14.89 (11.48–18.71)
11.60 (7.92–15.96)

14.89
11.60

17
11
23
11
35

4.36 (2.54–6.99)
5.38 (2.68–9.62)
12.99 (8.24–19.50)
6.51 (3.25–11.64)
15.83 (11.03–22.02)

1.41
0.83
1.11
1.20
2.54

12.08 (7.01–18.47)
13.22 (6.58–22.24)
20.72 (13.12–30.05)
9.14 (4.55–15.38)
13.80 (9.59–18.72)

12.08
13.22
20.72
9.14
13.80

18
27
52

1.55 (0.92–2.45)
2.32 (1.53–3.38)
4.48 (3.34–5.87)

2.15
1.52
1.89

8.39 (4.95–12.69)
17.81 (11.69–25.10)
27.45 (20.54–35.50)

8.39
17.81
27.45

292

5.39 (4.79–6.04)

32.04

9.11 (8.10–10.19)

9.11

211
81

6.32 (5.509–7.24)
3.88 (3.08–4.83)

18.50
13.54

11.40 (9.92–13.00)
5.98 (4.75–7.36)

11.40
5.98

72
50
42
43
85

3.59 (2.81–4.52)
5.51 (4.09–7.26)
5.36 (3.87–7.25)
5.59 (4.04–7.53)
8.87 (7.09–10.97)

7.20
3.69
4.76
5.48
10.77

10.00 (7.82–12.44)
13.56 (10.05–17.57)
8.82 (6.36–11.69)
7.85(5.68–10.37)
7.89(6.30–9.66)

10.00
13.56
8.82
7.85
7.89

84
88
120

1.55 (1.24–1.92)
1.62 (1.30–2.00)
2.21 (1.82–2.65)

9.89
6.95
8.45

8.50(6.77–10.41)
12.66(10.15–15.45)
14.20 (11.77–16.86)

8.50
12.66
14.20

*“Other” causes of death is an aggregate measure of causes that are neither accidental nor due to suicide. This category was collapsed
due to small cell sizes.
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Total deaths
Sex
Male
Female
Age (numeric, y)
Mean (SD)
Median (IQR)
Age category (y)
16–20
21–25
26–30
31–35
36–40
41–45
Cause of death
Accidental
Suicide
Other

Outpatient
cohort N (%)

stay hospitalization. Finally, 2863 patients were excluded
because they had a diagnosis of SSD in the 12 months
prior to cohort entry, resulting in a final hospitalization
cohort of 3178 patients. After accounting for 1090 patients who were in both the hospitalization and outpatient cohorts, there were 2382 patients in the first episode
SSD hospitalization cohort and 11 003 patients with a
first episode SSD diagnosis via outpatient enrollment.
Over the 5-year follow-up period, altogether 610 patients (93 in the hospital-diagnosed sample and 517 in
the outpatient-diagnosed sample) were censored due to
leaving the province.
The demographic and health care utilization characteristics in the 1 year prior to cohort entry for both cohorts are described in table 1. The hospital-diagnosed
cohort was similar to the outpatient-diagnosed cohort
with respect to sex, age, and neighborhood income distribution. A greater proportion of the hospital-diagnosed
vs outpatient-diagnosed cohort (16.1% vs 9.8%) had no
physician visits in the year prior to cohort entry. The
hospital-diagnosed cohort was also more likely to have

P. Kurdyak et al

Fig. 1. Five-year survival after cohort entry.

868

who died in the two cohorts, approximately 50% had not
seen a physician within 30 days of death. Within 1 year
of death, 18% of the hospital-diagnosed cohort and 11%
of the outpatient-diagnosed cohort had not seen a physician, but approximately 35% of the patients in both cohorts had a psychiatric hospitalization in the year prior
to death.
In the first sensitivity analysis that also included psychotic disorder not otherwise specified, the cohort was
larger, reflective of the inclusion of more subjects, but the
SMR was similar (Appendix table 1). In the second and
third sensitivity analyses requiring only two diagnoses of
SSD within 24 months and one diagnosis of SSD within
24 months, the cohorts shifted patients from the hospitaldiagnosed cohort to the outpatient-diagnosed cohort
and increased the cohort size slightly, but generated
very similar SMR results as in the primary study cohort
(Appendix table 2).
Discussion
Among Ontario residents with a first SSD diagnosis, 1
in 25 (4%) who had a first diagnosis during hospitalization and 1 in 40 (2.5%) who had a first diagnosis during
outpatient contact died within 5 years. Overall, patients who received a first diagnosis during hospitalization were over 13 times more likely to die within 5 years
compared with age-matched, population-based controls, and patients who were diagnosed in outpatient
settings were 9 times more likely to die. Additionally,
more than one-third of patients did not have physician
follow-up within 30 days of first diagnosis, and 50% of
those who died saw no physician in the 30 days prior
to the date of death. Furthermore, as many as 17.5%
of the hospital-diagnosed and 11.0% of the outpatientdiagnosed cohorts, had no physician contact even one
year prior to death.
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prior mental health-related hospitalizations (21.0% vs
16.6%; table 1).
Among the hospital-diagnosed cohort, 97 (4.1%) of
the patients died within 5 years of cohort entry. Among
the outpatient-diagnosed cohort, 292 (2.7%) died within
5 years of cohort entry. The sex, age, and causes of death
are described in table 2. A greater proportion of females
died in the hospital-diagnosed cohort (33.0% vs 27.7%).
The age at death was slightly younger in the outpatientdiagnosed cohort. A greater proportion of the outpatientdiagnosed cohort patients had an “accidental” cause of
death compared with hospital-diagnosed cohort patients
(28.8% vs 18.6%). The SMRs are described in table 3.
The overall age- and sex-standardized SMR for the hospitalized cohort was 13.62 (95% CI: 11.05–16.47) and the
overall SMR for the outpatient cohort was 9.11 (95% CI:
8.10–10.19). The SMR varied when stratified by sex, age,
and cause of death for both the hospital and outpatient
cohorts (table 3). A Kaplan–Meier 5-year survival curve
is shown in figure 1.
The health care utilization 30 days and 1 year following diagnosis is described in table 4. Notably, 37% of
the hospital-diagnosed cohort patients and 38% of the
outpatient-diagnosed cohort patients did not see any
physician within 30 days of cohort enrollment. By 1 year,
only 8% of the hospital-diagnosed cohort patients and
3% of the outpatient-diagnosed cohort patients still had
not seen a physician for mental health-related reasons.
Psychiatric hospitalizations were common following cohort entry. Among the hospital-diagnosed cohort patients, 13% experienced a psychiatric rehospitalization
within 30 days of index hospitalization discharge. Among
the outpatient-diagnosed cohort patients, 28% of patients
experienced a psychiatric hospitalization within 30 days
of cohort enrollment. Table 4 also shows the health care
utilization 30 days and 1 year prior to death among the
patients who died in each of the two cohorts. For patients

Mortality After the First Diagnosis of Schizophrenia

Table 4. Health service utilization 30 d and 1 y following cohort entry and prior to death
Hospital cohort N (%)

Outpatient cohort N (%)

Total
30 d following diagnosis
No visits
PCP visit(s)
Psychiatrist visit(s)
PCP and psychiatrist visit(s)
ED visit
Mental health related
Self-harm
Nonmental health related
Hospitalization
Mental health related
Nonmental health related
1 y following diagnosis
No visits
PCP visit(s)
Psychiatrist visit(s)
PCP and psychiatrist visit(s)
ED visit
Mental health related
Self-harm
Nonmental health related
Hospitalization
Mental health related
Nonmental health related
Health service utilization prior to death
Total deaths
30 d before death
Physician visits
No visits
PCP visit(s)
Psychiatrist visit(s)
PCP and psychiatrist visit(s)
ED visit
Mental health-related
Self-harm
Nonmental health-related
Hospitalization
Mental health-related
Nonmental health-related
1 y before death
Physician visits
No visits
PCP visit(s)
Psychiatrist visit(s)
PCP and psychiatrist visit(s)
ED visit
Mental health-related
Self-harm
Nonmental health-related
Hospitalization
Mental health-related
Nonmental health-related

2382

11 003

Standardized difference

877 (36.8)
818 (34.3)
982 (41.2)
344 (14.4)

4157 (37.8)
4151 (37.7)
3855 (35.0)
1422 (12.9)

0.02
0.07
0.13
0.04

156 (6.5)
8 (0.3)
213 (8.9)

447 (4.1)
34 (0.3)
684 (6.2)

0.11
0.00
0.10

301 (12.6)
35 (1.5)

3094 (28.1)
79 (0.7)

0.39
0.07

199 (8.4)
1778 (74.6)
1700 (71.4)
1333 (56.0)

328 (3.0)
9502 (86.4)
8003 (72.7)
6876 (62.5)

0.23
0.30
0.03
0.13

523 (22.0)
50 (2.1)
857 (36.0)

1914 (17.4)
191 (1.7)
3817 (34.7)

0.11
0.03
0.03

952 (40.0)
132 (5.5)

4598 (41.8)
522 (4.7)

0.04
0.04

97

292

0.08

46 (47.4%)
29 (29.9%)
21 (21.6%)
6 (6.2%)

143 (49.0%)
99 (33.9%)
68 (23.3%)
27 (9.2%)

0.03
0.09
0.04
0.11

7 (7.2%)
≤5
11 (11.3%)

25 (8.6%)
≤5
49 (16.8%)

0.05
0.21
0.16

6 (6.2%)
≤5

23 (7.9%)
12 (4.1%)

0.07
0.05

17 (17.5%)
63 (64.9%)
52 (53.6%)
38 (39.2%)

32 (11.0%)
213 (72.9%)
185 (63.4%)
140 (47.9%)

0.19
0.17
0.20
0.18

29 (29.9%)
≤5
55 (56.7%)

99 (33.9%)
18 (6.2%)
162 (55.5%)

0.09
0.04
0.02

36 (37.1%)
18 (18.6%)

104 (35.6%)
48 (16.4%)

0.03
0.06

The findings of this study are consistent with previous studies of mortality in first episode psychosis.3,14,15
There have been recent, population-based analyses of
the mortality gap in all adults with schizophrenia, and
these studies reveal that cardiovascular diseases, as well
as suicide, are significant contributors to the persistent

Downloaded from https://academic.oup.com/schizophreniabulletin/article/47/3/864/6103825 by guest on 08 August 2022

Health service utilization after cohort entry

mortality gap.1,2,16 This finding has led to a focus on addressing cardiovascular risk factors in individuals with
schizophrenia and other psychotic disorders.1 However,
in the period of time following first diagnosis, suicide,
and unnatural deaths, as was shown in our study, have
emerged as the main causes of death.4,5,14,17 This finding,
869
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(given prior work showing that engagement is higher in
early psychosis services23 and that service users have reduced mortality compared with nonusers6). The availability of such services stands in contrast to most other
jurisdictions around the world, other than countries such
as Australia, and Ireland, for instance.28 In the US, the
“EPI-NET” initiative and On-Track sites are closing the
gap through the creation of dedicated service networks
and communities of practice.29
In a population-based cohort of patients who were diagnosed with SSD in Ontario during hospitalization or outpatient contact, 5-year mortality was 13-fold and 9-fold
elevated, respectively, compared with the general population. These findings provide a public health imperative to
ensure timely and sustained access to care for this population, and to invest in the development of relatively lowcost interventions that can enable and support such access.
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along with early evidence that access to services focused
on individuals with first episode psychosis substantially
reduces mortality,6 suggests that addressing mortality
associated with schizophrenia likely requires aggressive
efforts to engage these individuals in treatment, and intensive suicide risk assessment and management in the
years following first diagnosis. “Light touch” efforts have
also been shown to reduce suicidal attempts following
ED visits as well, and are effective low-cost interventions
that can reduce mortality.18,19 System-level solutions are
required, given recent data from our group that suggest
that 60% of patients are not seeing a psychiatrist within
30 days of first diagnosis.20 Furthermore, in the present
cohort study, nearly 30% of patients did not see a psychiatrist within a year of first diagnosis.
There are many strengths to this study. First, we used
population-based data to develop a cohort that is followed for 5 years. The use of a validated algorithm meant
that we had a highly representative sample that included
patients who only engaged the system on an outpatient
basis at cohort entry. Second, we were able to follow all
patients for 5 years with minimal (5%) loss to follow-up.
Third, the outcome, mortality, is routinely measured
within the population-based data. Several limitations
are worth mentioning, however. First, our validated algorithm is, like most health administrative data algorithms, highly specific with relatively low sensitivity. We
conducted several sensitivity analyses to assess the impact of this, all of which revealed consistent results to
our primary analysis. However, we have likely missed
cases of schizophrenia for a number of reasons; requiring
health care utilization for cohort entry means that individuals who have a psychotic disorder but never access
the system will be missed. Second, our health care utilization measures include physician-based visits only. There
are nonphysician-based health care services for individuals with early psychosis that are not represented in our
data. We may have thus underestimated the true health
care utilization of the two cohorts. Nevertheless, access
to physicians is considered critical in the care of early
psychosis,21 as maintenance antipsychotic treatment for
SSD is considered crucial.22 Third, data were unavailable
to determine reasons for the lack of physician contact,
that is, whether this was related to patient nonadherence
due to lack of illness insight or illness worsening, fragmentation of care, or other reasons that could guide
interventions to mitigate the suboptimal engagement in
people with early phase SDD. Nevertheless, it is clear
that early, integrated care models for people with earlyphase SSD improve outcomes over usual care23 indicating
that such models should be favored whenever possible.
Finally, we did not capture risk factors for mortality,
such as comorbid substance use14 and nonadherence to
antipsychotic treatment.24–27 Finally, Ontario has some
catchmented, dedicated early psychosis services, which
could mean that our mortality data are an underestimate
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Appendix Table 1: Mortality and Standardized Mortality Ratios - Cohort including Psychotic Disorder Not Otherwise
Specified.
Total person
time of follow-up
(years)

Observed
Deaths

Crude Mortality rate
per 1,000 persons/year

Expected Death
Count

SMR (95% CI)

All-Cause Mortality

15019

130

8.66 (7.23–10.28)

9.04

14.38 (12.01–16.96)

8921
6098

80
50

8.97 (7.11–11.16)
8.20 (6.09–10.81)

5.03
4.02

15.92 (12.61–19.58)
12.45 (9.23–16.12)

5419
2397
2337
2188
2678

29
17
26
19
39

5.35 (3.58–7.69)
7.09 (4.13–11.36)
11.13 (7.27–16.30)
8.68 (5.23–13.56)
14.56 (10.36–19.91)

1.96
0.98
1.46
1.57
3.07

14.77 (9.90–20.67)
17.38 (10.08–26.57)
17.87 (11.62–25.31)
12.12 (7.27–18.16)
12.71 (9.03–17.00)

15019
15019
15019

28
41
61

1.86 (1.24–2.69)
2.73 (1.96–3.70)
4.06 (3.11–5.22)

2.75
1.94
2.39

10.18 (6.76–14.30)
21.11(15.16–28.10)
25.51 (19.52–32.33)

Sex
Male
Female
Age Category (years)
16–24
25–29
30–34
35–39
40–45
Cause of Death
Accidental
Suicide
Other

Outpatient-diagnosed Cohort N = 11,003
All-Cause Mortality
Sex
Male
Female
Age Category (years)
16–24
25–29
30–34
35–39
40–45
Cause of Death
Accidental
Suicide
Other

68293

403

41084
27209

280
123

25482
11374
9509
9554
12374
68293
68293
68293

5.90 (5.34–6.51)

40.53

9.94 (9.00–10.94)

6.82 (6.04–7.66)
4.52 (3.76–5.39)

23.12
17.40

12.11 (10.73–13.57)
7.07 (5.87–8.37)

88
67
50
63
135

3.45 (2.77–4.25)
5.89 (4.57–7.48)
5.26 (3.90–6.93)
6.59 (5.07–8.44)
10.91 (9.15–12.91)

9.16
4.63
5.79
6.82
14.05

9.61 (7.70–11.72)
14.48 (11.21–18.14)
8.63 (6.41–11.20)
9.24 (7.10–11.66)
9.61 (8.06–11.30)

108
109
186

1.58 (1.30–1.91)
1.60 (1.31–1.93)
2.72 (2.35–3.14)

12.44
8.75
10.71

8.68 (7.12–10.40)
12.46 (10.23–14.91)
17.36 (14.96–19.95)
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Hospital-diagnosed
Cohort N = 2,382
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Appendix Table 2: Mortality and Standardized Mortality Ratios – Cohorts requiring 2 psychotic disorder diagnoses
within 24 months and 1 psychotic disorder diagnosis within 12 months.
Hospital-diagnosed Cohort - Outpatient Diagnosis Requires 2 Billings in 24 Months.
N = 1,943

Observed
Deaths

Crude Mortality rate per
1,000 persons/year

Expected
Death Count

SMR (95% CI)

9,504

71

7.47 (5.83–9.42)

5.45

13.02 (10.17–16.23)

3,337
6,167

27
44

8.09 (5.33–11.77)
7.13 (5.18–9.58)

2.16
3.29

12.5 (8.23–17.66)
13.36 (9.71–17.62)

3,949
1,593
1,282
1,169
1,511

16
7
13
8
27

4.05 (2.32–6.58)
4.39 (1.77–9.05)
10.14 (5.40–17.34)
6.84 (2.95-13,48)
17.87 (11.78–26.00)

1.42
0.65
0.8
0.83
1.74

11.23 (6.42–17.47)
10.84 (4.27–20.22)
16.35 (8.62–26.28)
9.6 (4.12–17.47)
15.54 (10.22–21.92)

9,504
9,504
9,504

13
23
35

1.74
1.21
0.98

7.48 (3.96–12.08)
18.97 (12.03–27.57)
35.54 (24.86–48.53)

1.37 (0.73–2.34)
2.42 (1.53–3.63)
3.68 (2.57–5.12)

Outpatient-diagnosed Cohort - Outpatient Diagnosis Requires 2 Billings in 24 Months
N = 15,317
All-Cause Mortality
Sex
Female
Male
Age Category (years)
16–24
25–29
30–34
35–39
40+
Cause of Death
Accidental
Suicide
Other

Total person
time of follow-up

Observed
Deaths

Crude Mortality rate per
1,000 persons/year

Expected Death
Count

SMR (95% CI)

75,615

360

4.76 (4.28–5.28)

44.85

8.03 (7.22–8.88)

30,594
45,021

102
258

3.33 (2.72–4.05)
5.73 (5.05–6.47)

19.59
25.26

5.21 (4.25–6.27)
10.21 (9.01–11.50)

27,769
12,336
10,766
10,897
13,847

99
64
56
48
93

3.57 (2.90–4.34)
5.19 (4.00–6.63)
5.20 (3.93–6.75)
4.40 (3.25–5.84)
6.72 (5.42–8.23)

9.98
5.01
6.55
7.72
15.49

9.92 (8.06–11.97)
12.77 (9.84–16.10)
8.55 (6.46–10.94)
6.22 (4.58–8.10)
6 (4.85–7.29)

75,615
75,615
75,615

111
112
137

1.47 (1.21–1.77)
1.48 (1.22–1.78)
1.81 (1.52–2.14)

13.71
9.66
8.1

8.09 (6.66–9.67)
11.6 (9.55–13.84)
16.92 (14.20–19.86)

Expected Death
Count

SMR (95% CI)

Hospital-diagnosed Cohort - Outpatient Diagnosis Requires 1 Billing in 12 Months
N = 1,359
All-Cause Mortality
Sex
Female
Male
Age Category (years)
16–24
25–29
30–34
35–39
40+
Cause of Death
Accidental
Suicide
Other

872

Total person time
of follow-up

Observed Deaths

Crude Mortality rate per
1,000 persons/year

6,664

47

7.05 (5.18–9.38)

3.83

12.26 (9.01–16.03)

2,409
4,255

20
27

8.3 (5.07–12.82)
6.35 (4.18–9.23)

1.55
2.28

12.9 (7.87–19.18)
11.82 (7.80–16.73)

2,695
1,158
904
830
1,077

12
<=5
7
<=5
18

4.45 (2.30–7.78)
4.32 (1.40–10.08)
7.74 (3.11–15.95)
6.02 (1.96–14.06)
16.71 (9.91–26.41)

0.97
0.47
0.56
0.59
1.23

12.33 (6.36–20.36)
10.64 (3.36–22.01)
12.61 (4.95–23.48)
8.5 (2.67–17.53)
14.61 (8.65–22.18)

6,664
6,664
6,664

7
17
23

1.05 (0.42–2.16)
2.55 (1.49–4.08)
3.45 (2.19–5.18)

1.22
0.85
0.69

5.74 (2.27–10.78)
19.99 (11.62–30.64)
33.18 (21.10–48.35)
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All-Cause Mortality
Sex
Female
Male
Age Category (years)
16–24
25–29
30–34
35–39
40+
Cause of Death
Accidental
Suicide
Other

Total person time
of follow-up

Mortality After the First Diagnosis of Schizophrenia

Appendix Table 2 Continued
Outpatient-diagnosed Cohort - Outpatient Diagnosis Requires 1 Billing in 12 Months
N = 28,057

Observed Deaths

Crude Mortality rate per
1,000 persons/year

Expected Death
Count

138,596

616

4.44 (4.10–4.81)

84.21

7.31 (6.75–7.90)

61,921
76,675

195
421

3.15 (2.72–3.62)
5.49 (4.98–6.04)

39.57
44.64

4.93 (4.26–5.64)
9.43 (8.55–10.35)

47,084
22,876
20,445
20,669
27,522

131
97
105
97
186

2.78 (2.33–3.30)
4.24 (3.44–5.17)
5.14 (4.20–6.22)
4.69 (3.81–5.73)
6.76 (5.82–7.80)

16.89
9.26
12.44
14.65
30.82

7.76 (6.48–9.14)
10.48 (8.49–12.66)
8.44 (6.90–10.13)
6.62 (5.37–8.00)
6.04 (5.20–6.93)

138,596
138,596
138,596

181
175
260

1.31 (1.12–1.51)
1.26 (1.08–1.46)
1.88 (1.65–2.12)

17.8
25.15
15.21

SMR (95% CI)

9.83 (8.74–11.70)
7.2 (5.97–8.03)
17.1 (15.08–19.24)

Appendix Figure 1: Cohort Flow Chart.
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